{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '11.4.2.', 'Pharmacodynamic Studies', '11.4.2.1. Bone Marrow Aspirates for PDn', 'Bone marrow aspirate will be collected at Screening to isolate plasma, non-tumor CD138- and', 'tumor CD138+ cell fractions for subsequent PDn studies. Studies may include transcriptomic,', 'genomic and/or proteomic analyses to identify predictive biomarkers of selinexor response and', \"to characterize the knowledge of selinexor's mechanism of action. In addition, tumor cells will\", 'be used to assess the presence of the high risk mutations including del(17p), t(14;16) and t(4;14)', 'translocations and chromosome 1q21 amplification. Cytogenetic analysis by karyotyping and', 'FISH will be performed at a central laboratory to identify specific chromosomal translocations at', 'sites known to show rearrangements in MM.', 'Aspirate samples containing patient DNA may be used for pharmacogenetic research to do the', 'following:', 'study the causes of human diseases', 'help understand how different individuals respond to drugs', 'obtain information to help develop new methods to diagnose and treat diseases', 'The samples may be stored up to 15 years, depending on the laws of country where the study is', 'conducted. The samples will be labeled with a code rather than with patient name or any other', 'detail that could be used to identify the patient. These samples will be stored under the control of', 'the Sponsor.', 'Details of PDn sample collection and processing can be found in the Study Manual.', '11.5.', 'Safety Assessments', 'Safety evaluations will be performed as described below. Refer to Table 2 for the timing of all', 'safety assessments.', '11.5.1.', 'Clinical Safety Assessments', '11.5.1.1. Weight, Height, and BSA', 'Height (without shoes) in centimeters and weight (indoor clothing without shoes) in kilograms', 'will be measured. BSA will be calculated by the Dubois (Dubois 1916) or Mosteller (Mosteller', '1987) method to determine the volume of bortezomib to be administered and to ensure that an', \"individual patient's selinexor dose does not exceed 70 mg/m\u00b2. In no case may the selinexor dose\", \"exceed 70 mg/m\u00b2 per dose for any patient. If the patient's weight fluctuates substantially from\", 'baseline (ie, >20%) during treatment, BSA should be recalculated.', '11.5.1.2. Physical Examination, Vital Signs, and ECOG Performance Status', 'Complete physical examinations should include general appearance, skin, neck, eyes, ears, nose,', 'throat, lungs, heart, abdomen, back, lymph nodes, extremities, and neurological examinations.', 'Symptom-directed physical examinations should include body systems as appropriate, including', 'the presence/absence or change in size of plasmacytomas identified at Screening. These', 'examinations will be performed according to the standards at each institution.', 'Confidential', 'Page 81', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Information about the physical examinations must be present in the source documentation at the', 'study site. Clinically relevant findings made after the start of study dosing, which meet the', 'definition of an AE, must be recorded in the AE eCRF.', 'Vital signs include systolic and diastolic blood pressure (BP), pulse measurements, and body', 'temperature (\u00b0C or \u00b0F). Vital signs should be assessed predose on the scheduled visit day, if', 'possible. BP and pulse rate should be measured after the patient has been in a supine or sitting', 'position for 5 minutes. BP should be assessed on the same arm throughout the study. Note: If the', 'visit for MM disease assessments occurs on the same day as the in-clinic dosing visit, vital signs', 'should only be performed once.', 'ECOG performance status assessments (Oken 1982) will be performed during the study to assess', 'how the disease affects the daily living abilities of the patients.', '11.5.1.3. Electrocardiography', 'A standard 12-lead ECG will be performed. Patients must rest for at least 5 minutes prior to the', 'ECG recording. The Investigator will interpret the ECG using 1 of the following categories:', 'normal, abnormal but not clinically significant, or abnormal and clinically significant. The date', 'and time the ECG was performed and the following parameters will be recorded in the eCRF:', \"heart rate, PR interval, QT interval, QRS interval, and QT corrected using Fridericia's formula\", '(Fridericia 1920).', '11.5.1.4. Ophthalmic Examination', 'An ophthalmic examination by an optometrist or ophthalmologist is required prior to the first', 'dose of study treatment and should be repeated if clinically indicated during the study (eg,', 'monitoring of pre-existing cataracts, visual disturbances).', 'Any patient reporting de-novo or worsening of visual symptoms should immediately be referred', 'for further examination. All visual symptoms must be documented in the eCRF.', 'The ophthalmic examination is to include the following:', 'Prior to dilation:', '- best corrected visual acuity', '- slit lamp examination (for cataracts or other abnormalities)', '- tonometry', 'Following dilation:', '- fundoscopy', '-', 'slit lamp examination to document lens clarity', 'If a cataract/lens opacity is seen during the examination, the cataract/lens opacity will be graded', 'according to the American Optometric Association (AOA) Cataract Grading System, which is', 'available on the AOA website (www.aoa.org).', 'Confidential', 'Page 82', 'Version 4.0']\n\n###\n\n", "completion": "END"}